PRIMARY OBJECTIVES:
I. To determine the feasibility and utility of 68Ga-PSMA PET imaging patients with ovarian cancer.
II. Determine detection sensitivity for nodal metastases for PSMA PET stratified by node size.
SECONDARY OBJECTIVES:
I. To assess the correlation between targeted molecular uptake of 68Ga-PSMA PET and PSMA expression in surgical resection specimens.
EXPLORATORY OBJECTIVES:
I. To explore heterogeneity of 68Ga-PSMA PET uptake in cases of metastatic ovarian cancer.
II. To determine the relationship between 68Ga-PSMA PET uptake, diffusion weighted imaging, and MRI-derived tumor perfusion.
OUTLINE:
Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV) over 1-2 minutes. After about 60 minutes, patients undergo PET/magnetic resonance imaging (MRI) for approximately over 50-60 minutes. Patients may undergo an optional repeat gallium Ga 68-labeled PSMA-11 PET between 8 and 12 weeks after completion of the first PET/MRI.
After completion of study, patients are followed up at 28 days.
